Company Overview and News
2018-10-08 247wallst - 1
Stocks were looking to open lower on Monday, but it was expected to be a fairly quiet day with the Columbus Day holiday keeping part of the banking system closed. U.S. equity indexes are just under all-time highs, but investors have been seeing lower upside from buying on market pullbacks than in prior years. Now the investing community has to consider how they want to position their investments for the rest of 2018 and into 2019.
HAL FB ABT WMT HUN AAPL CAG TMHC ABT SLB EA GE GEC VOD VOD CBT BHGE KMB PBR MDT BHI BLK VODPF TRI GNE SCL SLB
2018-10-08 seekingalpha - 3
E&P companies that are neither top institutional favorites nor companies I would classify in my Bottom of the Barrel Club may have wide appeal to investors.
GIS XOM PXD QEP AR CRZO WMB XOG NBL WLL PDCE SRCI SM CTLR NFX RRS WPX ESTE RGRLF RRC WTI CLR OXY AEUA HAL APC APA WPXP DVN CXO PE RRL COP ROSEU RSPP REI AMR EGN JAG ROSE CDEV D COG EOG RGRYY HP CVX LPI HK FANG
As oil prices stay above $55/barrel and companies make drilling plans for next year, the subdued price levels of oilfield service company stocks could make them good investments.
HAL BHI PTEN SLB GEC GE WFT BHGE GNE SLB NBR
It has been hard for investors to make some of the same gains in the oil and gas segment since oil prices have recovered handily. That may be about to change, or at least that is the take of Morgan Stanley. The firm issued a series of major upside calls for its clients looking to profit within oil and gas.
WFCNP HAL MS RIG WFC SLB BHGE NBR DO DRQ BHI TRI SCL SLB SGAZF
2018-09-19 247wallst - 1
Stocks were indicated to open lower on Wednesday, but this was after a solid day of gains on Tuesday. U.S. equity indexes remain very close to their all-time highs. Unfortunately, most international markets are no longer anywhere close to their highs. One issue that has to be considered is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
HAL ARPO D SPWR BBU BHGE KBR DO DRQ ERIC BHI ETFC JNPR BGNE TRI NOK MS
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
Stocks were indicated to open lower on Tuesday morning as continued profit-taking in September is a theme. Despite the choppy markets, it’s important to know that the major stock market indexes are still quite close to all-time highs. Investors also need to consider that buying the sell-offs has so far in 2018 been less rewarding than in prior years.
PCG HAL NOV WDC NKE GNRC EGN AEP MYGN MS CBS CBS.A BHGE CBS.WD BHI CZR TRI CPV FANG
To be fair, not all shale gas drilling is slowing, but in the Permian Basin, which has seen the most incandescent growth in recent years, according to the Financial Times, growth is slowing markedly, according to Schlumberger (NYSE:SLB), Halliburton (NYSE:HAL) and the U.K.'s Weir Group (OTCPK:WEGRY) (OTCPK:WEIGY) - all major suppliers to, or active players in, the fracking industry.
HAL WEIGF WEIR SLB WEIGY WEGRY EOG
In the latest edition of the Numbers Report, we’ll take a look at some of the most interesting figures put out this week in the energy sector. Each week we’ll dig into some data and provide a bit of explanation on what drives the numbers.
2018-09-05 investorplace - 1
If you’re buying General Electric (NYSE:GE) today, you’re buying it based on nostalgia. The current company is a mess, mostly a power unit, that was once France’s Alstom, whose acquisition was said to be its “best deal ever” when it closed in 2015.
HAL BHI GE GEC BHGE GNE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to HAL / Halliburton Co. on message board site Silicon Investor.
as of ET